References
- Shi J Kantoff PW Wooster R et al. Cancer nanomedicine: progress, challenges and opportunities . Nat. Rev. Cancer17 ( 1 ), 20 – 37 ( 2017 ).
- Karimi M Zare H Bakhshian Nik A et al. Nanotechnology in diagnosis and treatment of coronary artery disease . Nanomedicine11 ( 5 ), 513 – 530 ( 2016 ).
- Veiseh O Tang BC Whitehead KA et al. Managing diabetes with nanomedicine: challenges and opportunities . Nat. Rev. Drug Discov.14 ( 1 ), 45 – 57 ( 2015 ).
- Gendelman HE Anantharam V Bronich T et al. Nanoneuromedicines for degenerative, inflammatory, and infectious nervous system diseases . Nanomedicine11 ( 3 ), 751 – 767 ( 2015 ).
- Zuckerman JE Davis ME . Clinical experiences with systemically administered siRNA-based therapeutics in cancer . Nat. Rev. Drug Discov.14 ( 12 ), 843 – 856 ( 2015 ).
- Blanco E Shen H Ferrari M . Principles of nanoparticle design for overcoming biological barriers to drug delivery . Nat. Biotechnol.33 ( 9 ), 941 – 951 ( 2015 ).
- Cabral H Kataoka K . Progress of drug-loaded polymeric micelles into clinical studies . J. Control. Release190 , 465 – 476 ( 2014 ).
- von Roemeling C Jiang W Chan CK et al. Breaking down the barriers to precision cancer nanomedicine . Trends Biotechnol.35 ( 2 ), 159 – 171 ( 2017 ).
- Lu Y Aimetti AA Langer R et al. Bioresponsive materials . Nat. Rev. Mater.2 , 16075 ( 2016 ).
- Fang J Nakamura H Maeda H . The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect . Adv. Drug Deliv. Rev.63 ( 3 ), 136 – 151 ( 2011 ).
- Salvati A Pitek AS Monopoli MP et al. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface . Nat. Nanotechnol.8 ( 2 ), 137 – 143 ( 2013 ).
- Rodriguez PL Harada T Christian DA et al. Minimal “self” peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles . Science339 ( 6122 ), 971 – 975 ( 2013 ).
- Chauhan VP Stylianopoulos T Martin JD et al. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner . Nat. Nanotechnol.7 ( 6 ), 383 – 388 ( 2012 ).
- Swartz MA Lund AW . Lymphatic and interstitial flow in the tumour microenvironment: linking mechanobiology with immunity . Nat. Rev. Cancer12 ( 3 ), 210 – 219 ( 2012 ).
- Wilhelm S Tavares AJ Dai Q et al. Analysis of nanoparticle delivery to tumours . Nat. Rev. Mater.1 , 16014 ( 2016 ).
- Venditto VJ Szoka FC Jr . Cancer nanomedicines: so many papers and so few drugs!Adv. Drug Deliv. Rev.65 ( 1 ), 80 – 88 ( 2013 ).
- Mitragotri S Burke PA Langer R . Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies . Nat. Rev. Drug Discov.13 ( 9 ), 655 – 672 ( 2014 ).
- Aouadi M Tesz GJ Nicoloro SM et al. Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation . Nature458 ( 7242 ), 1180 – 1184 ( 2009 ).
- Zhou X Zhang XJ Han SL et al. Yeast microcapsule-mediated targeted delivery of diverse nanoparticles for imaging and therapy via the oral route . Nano Lett.17 ( 2 ), 1056 – 1064 ( 2017 ).
- Samuelsen AB Schrezenmeir J Knutsen SH . Effects of orally administered yeast-derived beta-glucans: a review . Mol. Nutr. Food Res.58 ( 1 ), 183 – 193 ( 2014 ).